Cordyceps Sinensis also called as ophiocordyceps sinensis is combination of parasitic fungus species and dead caterpillars that offer several potential health applications. It has been in use in traditional Chinese and Tibetan medicines as remedy for around 21 ailments such as low immunity, high blood pressure etc. Cordyceps spores grows inside the caterpillar’s body and infects it, thus slowly degrading the living larva and mummifies it in the soil. A cordyceps stem eventually emerges from head part of the caterpillar.
Major active ingredients in cordyceps sinensis extract include cordycepin, adenosine, exopolysaccharide fraction (EPSF), cordyglucans, and monosaccharide saponin. Scientific studies and clinical trials found that cordyceps sinensis extract can aid treatment of diabetes, high cholesterol, and hypertension. Furthermore, it boosts immunity and acts as stress reliever in stress related disorders.
Cordyceps Sinensis is available as health supplement in tablet, powder, and capsule form in major developed markets. Regulatory bodies such as USFDA has have approved use of cordyceps sinensis extract as dietary supplement.
Cordyceps Sinensis Market - Market Dynamics
Cordyceps sinensis offers medicinal properties such as cholesterol reduction, stimulation of the immune system, faster recovery from bronchitis, and other respiratory diseases, and increases efficiency of the circulatory system. Furthermore, it has anti-cancer properties and can be used in treatment of liver-associated diseases. It provides enhanced recovery from chemotherapy, improves libido, a general body adaptogen (enhanced body energy and strength)
High prevalence of chronic diseases such as cardiovascular disease, cancer, diabetes, and respiratory diseases would lead to increasing adoption of preventive healthcare products made from cordyceps sinensis extracts, which in turn would aid in growth of the cordyceps sinensis extract market. According to World Health Organizations statistics, in 2018, non-communicable diseases are responsible for over 41 million deaths, annually, which is equivalent to 71% of all deaths, worldwide. Furthermore, according to the same source cardiovascular diseases causes over 17.9 million deaths annually, followed by cancer (9.0 million), respiratory diseases (3.9million), and diabetes (1.6 million), respectively.
High prevalence of autoimmune and stress related disorders across the world, especially in developed regions such as North America and Europe. According to American Autoimmune Related Disease Association, more than 50 million people in the U.S. were affected by autoimmune disease in 2017. This would be another major factor driving growth of the cordyceps sinensis extract market. Increased preference for natural remedy for correcting chronic disease is new trend in world including U.S.
However, high cost of cordyceps sinensis extracts is expected to be a major factor deterring the market growth. Insufficient clinical evidence for many diseases such as cancer and diabetes may limit market growth for cordyceps sinensis extract. Furthermore, it is difficult to scale up the artificial cultivation of cordyceps sinensis species. High cost of cordyceps sinensis in the international market often leads to malpractice of adulteration and substitution in the extracts.
Cordyceps Sinensis Market - Regional Insights
Geographically, the global cordyceps sinensis extract market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to lead the market during the forecast period, followed by Europe.
High prevalence of chronic diseases in the U.S. is expected to be a major factor supporting the market growth. According to Centre for Disease Control and Prevention, seven of the top ten causes of deaths in the U.S., in 2014 were chronic diseases, heart diseases, and cancer, which together accounted for over 46% of the deaths in the country. Furthermore, increasing number of patients with mental disorders is expected to significantly expand adoption of cordyceps sinensis extracts as it has immense benefits in lowering symptoms related to mental disorder. According to Anxiety and Depression Association of America in 2017, anxiety disorders are the most common mental illness in the U.S., affecting around 40 million adults aged 18 years and above, or 18.1% of the population, annually. However, only 36.9% of those suffering from anxiety receive treatment.
Asia Pacific is expected to show significant growth in the global cordyceps sinensis extract market over the forecast period. This is due the region being a major producer of cordyceps sinensis extracts, especially in China. According to data presented by the Ministry of Agriculture and Rural Affairs of the Peoples Republic of China in 2011, China has 200,000 kg of Cordyceps and 120,000 kg was harvested. Qinghai and Tibet regions exports around 20,000 kg of cordyceps sinensis to the U.S., Japan, Korea, Europe, South East Asia, Hong Kong, Macao and Taiwan etc. with an annual export of over 20,000 kg. Furthermore, rising prevalence of chronic diseases and increasing adoption of traditional medicines for the treatment of such diseases in the region is expected to propel growth of the cordyceps sinensis extract market. As per World Health Organizations’ factsheet in 2018, 1 in 3
Cordyceps Sinensis Market - Competitive Landscape
Key players operating in the global cordyceps sinensis market include Naturalin, Active Organics, Quyuan sunnycare Inc., Kangzhou, HERBSINO, SOST, Health Choice Limited, Zhongke Group, and Nutra Green.
Cordyceps Sinensis Market - Market Taxonomy
On the basis of dosage form, the global cordyceps sinensis market is segmented into -
On the basis of application, the global cordyceps sinensis market is segmented into -:
On the basis of distribution channel, the global cordyceps sinensis market is segmented into -:
On the basis of geography, the global cordyceps sinensis market is segmented into:
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients